Biotechnology
Compare Stocks
2 / 10Stock Comparison
ABSI vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ABSI vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $872M | $1669.52T |
| Revenue (TTM) | $3M | $0.00 |
| Net Income (TTM) | $-115M | $-168M |
| Gross Margin | -13.2% | — |
| Operating Margin | -44.8% | — |
| Total Debt | $5M | $22M |
| Cash & Equiv. | $20M | $194M |
ABSI vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Absci Corporation (ABSI) | 100 | 20.9 | -79.1% |
| DBV Technologies S.… (DBVT) | 100 | 38.7 | -61.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABSI vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ABSI is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -38.2%, EPS growth 10.6%, 3Y rev CAGR -21.3%
- -74.0% 10Y total return vs DBVT's -87.1%
- Lower volatility, beta 2.82, Low D/E 2.8%, current ratio 6.57x
DBVT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs ABSI's -41.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -38.2% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs ABSI's -41.1% | |
| Stability / Safety | Beta 1.26 vs ABSI's 2.82 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +110.7% vs ABSI's +95.5% | |
| Efficiency (ROA) | -51.0% ROA vs DBVT's -89.0% |
ABSI vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ABSI and DBVT operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3M | $0 |
| EBITDAEarnings before interest/tax | -$114M | -$112M |
| Net IncomeAfter-tax profit | -$115M | -$168M |
| Free Cash FlowCash after capex | -$94M | -$151M |
| Gross MarginGross profit ÷ Revenue | -13.2% | — |
| Operating MarginEBIT ÷ Revenue | -44.8% | — |
| Net MarginNet income ÷ Revenue | -41.1% | — |
| FCF MarginFCF ÷ Revenue | -33.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +20.0% | +91.5% |
Valuation Metrics
Evenly matched — ABSI and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $872M | $1669.52T |
| Enterprise ValueMkt cap + debt − cash | $857M | $1669.52T |
| Trailing P/EPrice ÷ TTM EPS | -6.68x | -0.74x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 311.45x | — |
| Price / BookPrice ÷ Book value/share | 4.05x | 0.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ABSI leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
ABSI delivers a -59.7% return on equity — every $100 of shareholder capital generates $-60 in annual profit, vs $-130 for DBVT. ABSI carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -59.7% | -130.2% |
| ROA (TTM)Return on assets | -51.0% | -89.0% |
| ROICReturn on invested capital | -58.0% | — |
| ROCEReturn on capital employed | -65.9% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.13x |
| Net DebtTotal debt minus cash | -$15M | -$172M |
| Cash & Equiv.Liquid assets | $20M | $194M |
| Total DebtShort + long-term debt | $5M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -592.44x | -189.82x |
Total Returns (Dividends Reinvested)
ABSI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,041 today (with dividends reinvested), compared to $2,598 for ABSI. Over the past 12 months, DBVT leads with a +110.7% total return vs ABSI's +95.5%. The 3-year compound annual growth rate (CAGR) favors ABSI at 59.2% vs DBVT's 5.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +55.4% | +2.3% |
| 1-Year ReturnPast 12 months | +95.5% | +110.7% |
| 3-Year ReturnCumulative with dividends | +303.6% | +18.1% |
| 5-Year ReturnCumulative with dividends | -74.0% | -69.6% |
| 10-Year ReturnCumulative with dividends | -74.0% | -87.1% |
| CAGR (3Y)Annualised 3-year return | +59.2% | +5.7% |
Risk & Volatility
Evenly matched — ABSI and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than ABSI's 2.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABSI currently trades 97.6% from its 52-week high vs DBVT's 74.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.82x | 1.26x |
| 52-Week HighHighest price in past year | $5.75 | $26.18 |
| 52-Week LowLowest price in past year | $2.24 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +97.6% | +74.4% |
| RSI (14)Momentum oscillator 0–100 | 81.7 | 43.7 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 249K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ABSI as "Buy" and DBVT as "Buy". Consensus price targets imply 137.7% upside for DBVT (target: $46) vs 9.8% for ABSI (target: $6).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.16 | $46.33 |
| # AnalystsCovering analysts | 12 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ABSI leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 2 tied.
ABSI vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ABSI or DBVT a better buy right now?
Analysts rate Absci Corporation (ABSI) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABSI or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 6%, compared to -74. 0% for Absci Corporation (ABSI). Over 10 years, the gap is even starker: ABSI returned -72. 4% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABSI or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Absci Corporation's 2. 82β — meaning ABSI is approximately 125% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — ABSI or DBVT?
On earnings-per-share growth, the picture is similar: Absci Corporation grew EPS 10.
6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABSI or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -41. 1% for Absci Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ABSI or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ABSI or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Absci Corporation (ABSI) carries a higher beta of 2. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -86. 8%, ABSI: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ABSI and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.